Transplantation and Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada.
Manitoba Centre for Proteomics and Systems Biology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Transplantation. 2018 Mar;102(3):521-529. doi: 10.1097/TP.0000000000001931.
Urinary CXC chemokine ligand 10 (CXCL10) is a promising biomarker for subclinical tubulointerstitial inflammation, but limited data exist regarding its correlation with (micro)vascular inflammation. Furthermore, no study has evaluated whether concomitant serum CXCL10 improves the discrimination for (micro)vascular inflammation.
We investigated whether serum/urinary CXCL10 reflect subclinical inflammation within different renal compartments. Patients (n = 107) with 107 surveillance biopsies were classified as: normal histology (n = 47), normal histology with polyomavirus BK (BKV) or cytomegalovirus (CMV) viremia (n = 17), moderate-severe tubulointerstitial inflammation (tubulitis ≥2, n = 18), pure microvascular inflammation (n = 15), and isolated v lesions (n = 10). Serum and urinary CXCL10 Enzyme-linked Immunosorbent Assay was performed. An independent validation set was evaluated for urine CXCL10: normal histology (n = 14), normal histology with BKV or CMV viremia (n = 19), tubulitis ≥2 (n = 15), pure microvascular inflammation (n = 41), and isolated v lesions (n = 14).
Elevated urinary CXCL10 reflected inflammation within the tubulointerstitial (urinary CXCL10/creatinine, 1.23 ng/mmol vs 0.46 ng/mmol; P = 0.02; area under the curve, 0.69; P = 0.001) and microvascular compartments (urinary CXCL10/creatinine, 1.72 ng/mmol vs 0.46 ng/mmol; P = 0.03; area under the curve, 0.69; P = 0.02) compared to normal histology. Intriguingly, urinary CXCL10 was predominantly elevated with peritubular capillaritis, but not glomerulitis (P = 0.04). Furthermore, urinary CXCL10 corresponded with BKV, but not CMV viremia (P = 0.02). These urine CXCL10 findings were confirmed in the independent validation set. Finally, serum CXCL10 was elevated with BKV and CMV viremia but was not associated with microvascular or vascular inflammation (P ≥ 0.19).
Urinary CXCL10 reflects subclinical inflammation within the tubulointerstitial and peritubular capillary spaces, but not the vascular/systemic compartments; this was consistent with BKV (tubulointerstitial) and CMV viremia (systemic). Serum CXCL10 was not a useful marker for (micro)vascular inflammation.
尿趋化因子配体 10(CXCL10)是一种有前途的亚临床肾小管间质炎症的生物标志物,但关于其与(微)血管炎症的相关性的相关数据有限。此外,尚无研究评估同时检测血清 CXCL10 是否能提高对(微)血管炎症的鉴别能力。
我们研究了血清/尿液 CXCL10 是否反映了不同肾脏部位的亚临床炎症。107 例接受 107 例监测性活检的患者被分为:正常组织学(n=47),伴有 BK 多瘤病毒(BKV)或巨细胞病毒(CMV)病毒血症的正常组织学(n=17),中重度肾小管间质炎症(tubulitis≥2,n=18),单纯微血管炎症(n=15)和孤立性血管病变(n=10)。进行了血清和尿液 CXCL10 酶联免疫吸附试验。对独立验证组进行尿液 CXCL10 检测:正常组织学(n=14),伴有 BKV 或 CMV 病毒血症的正常组织学(n=19),tubulitis≥2(n=15),单纯微血管炎症(n=41)和孤立性血管病变(n=14)。
尿液 CXCL10 升高反映了肾小管间质(尿液 CXCL10/肌酐,1.23ng/mmol 与 0.46ng/mmol;P=0.02;曲线下面积,0.69;P=0.001)和微血管(尿液 CXCL10/肌酐,1.72ng/mmol 与 0.46ng/mmol;P=0.03;曲线下面积,0.69;P=0.02)部位的炎症。有趣的是,尿液 CXCL10 主要在肾小管周毛细血管炎时升高,而在肾小球肾炎时不升高(P=0.04)。此外,尿液 CXCL10 与 BKV 相关,但与 CMV 病毒血症无关(P=0.02)。在独立验证组中证实了这些尿液 CXCL10 发现。最后,血清 CXCL10 在 BKV 和 CMV 病毒血症时升高,但与微血管或血管炎症无关(P≥0.19)。
尿液 CXCL10 反映了肾小管间质和肾小管周毛细血管腔内的亚临床炎症,但不反映血管/系统部位;这与 BKV(肾小管间质)和 CMV 病毒血症(系统性)一致。血清 CXCL10 不是(微)血管炎症的有用标志物。